Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
For most adults, the RSV vaccine is currently given as a single lifetime dose rather than repeated every year, and people who have already received one are not advised to get another at this time. Timing differs for pregnancy (one dose in a defined window during the season) and for infants, who may receive a protective antibody injection each RSV season, and future booster guidance may change as research continues. Several factors affect whether and when you might need another dose, including your age, health conditions, and when your first dose was given, so review the complete details below before deciding.
If you are coughing, wheezing, or feeling feverish and unsure whether RSV, flu, or COVID could be behind it, guessing can delay care that works best early. A free, instant, online symptom check can help you understand what your symptoms may point to and what sensible next steps look like, in just a few minutes and without leaving home.
Last reviewed for medical accuracy: 09/23/2026
Respiratory syncytial virus (RSV) can cause serious lung infections, especially in older adults and young children. With the recent approval of RSV vaccines for adults and pregnant people, many are asking: “RSV vaccine how often do I need it?” Below is a clear, up-to-date overview based on CDC and FDA guidance.
At this point, there’s no recommendation for more than one dose within a single season. Future data may refine timing or booster needs.
Currently, vaccines are not approved for infants. Instead, high-risk babies (preterm, certain heart or lung conditions) may receive nirsevimab, a long-acting antibody. This is given as:
Check with your pediatrician to see if your child qualifies.
Most people tolerate the RSV vaccine well. Common side effects include:
These generally resolve in a day or two. Serious allergic reactions are rare.
Even with vaccination, no vaccine is 100% effective. If you develop cough, fever, wheezing or difficulty breathing:
Guidelines evolve as more data emerge. Always discuss with your health-care provider:
If you have a medical emergency (severe difficulty breathing, chest pain, sudden confusion), seek immediate care or call emergency services.
Staying up to date on your RSV vaccine—especially if you’re 60 or older or pregnant—can help keep you and your loved ones healthier through RSV season. Always “speak to a doctor” about any serious or life-threatening concerns.
(References)
* Chu HY, Englund JA. Maternal immunization. Birth Defects Res. 2017 Mar 15;109(5):379-386. doi: 10.1002/bdra.23547. PMID: 28398678.
* Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, McGrory SB, Gomme E, Anderson M, Roberts JP, Scott DA, Jansen KU, Gruber WC, Dormitzer PR, Gurtman AC. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N Engl J Med. 2022 Apr 28;386(17):1615-1626. doi: 10.1056/NEJMoa2106062. PMID: 35476650.
* Lu BN, Zhu KL, Cui XM, Yao L, Wang XJ, Wang GL, Duan LJ, Qian A, Ma MJ. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Clin Immunol. 2022 Nov;244:109103. doi: 10.1016/j.clim.2022.109103. Epub 2022 Aug 29. PMID: 36049602; PMCID: PMC9423872.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.
* Blauvelt CA, Zeme M, Natarajan A, Epstein A, Roh ME, Morales A, Bourdoud N, Flaherman VJ, Prahl MK, Gaw SL. Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates. JAMA Netw Open. 2025 Feb 3;8(2):e2460735. doi: 10.1001/jamanetworkopen.2024.60735. Epub 2025 Feb 3. PMID: 39969879; PMCID: PMC11840647.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 study group. Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14. PMID: 40245915.
* Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28;334(16):1442-1451. doi: 10.1001/jama.2025.15896. PMID: 40884491; PMCID: PMC12398767.
* Ruuskanen O, Valtonen M, Heinonen OJ, Waris M, Mertsola J. Vaccinations for Elite Athletes. Vaccines (Basel). 2025 Aug 31;13(9). doi: 10.3390/vaccines13090931. Epub 2025 Aug 31. PMID: 41012134; PMCID: PMC12474241.
* Saif-Ur-Rahman KM, King C, Whelan SO, Blair M, Donohue S, Madden C, Kothari K, Sommer I, Harder T, Dauby N, Moustsen-Helms IR, Ruta S, Frère J, Schönfeld V, Poukka E, Lutsar I, Olsson K, Melidou A, Adel Ali K, Dwan K, Devane D. Efficacy and safety of respiratory syncytial virus vaccines. Cochrane Database Syst Rev. 2025 Sep 29;9(9):CD016131. doi: 10.1002/14651858.CD016131. Epub 2025 Sep 29. PMID: 41016728; PMCID: PMC12476935.
* Höck M, Borena W, Brunner J, Wechselberger K, Scheiring J, Ralser E, Pupp Peglow U, Wöckinger P, D'Costa E, Kaiser V, Kapelari K, Gerold G, Müller T, Kiechl-Kohlendorfer U, Griesmaier E. Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria. Front Public Health. 2025;13:1686581. doi: 10.3389/fpubh.2025.1686581. Epub 2025 Oct 20. PMID: 41189975; PMCID: PMC12580268.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.